RIPK1 and Alzheimer disease: For example, Ofengeim et al. found that RIPK1 was activated in human AD pathological samples, and pharmacological and genetic inhibition of RIPK1 could reduce Aβ burden, inflammatory cytokine expression and memory deficits in an AD mouse model [9].